-
Mashup Score: 0
Siamak Daneshmand, MD, discusses initial findings from the phase 2b SUNRISE-1 trial exploring the novel intravesical chemotherapy delivery system TAR-200 in non–muscle-invasive bladder cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC - 12 month(s) ago
Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC @chumontreal @AmerUrological #AUA23 #pcsm https://t.co/n3dFjYzMWm
-
-
Mashup Score: 3
Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC @UrogerliMD @MoffittNews @AmerUrological #AUA23 #blcsm https://t.co/Jo1ejdKidj
-
-
Mashup Score: 2
“We have to be intentional in order to design our trials so that we have a better participation of those groups,” says Larissa V. Rodriguez, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Larissa Rodríguez recaps an #AUA23 symposium on disparities in urologic research. #urology #urologist @WCMUrology @RodriguezMDUrol Watch now: https://t.co/vUnrgBCLGe
-
-
Mashup Score: 4
In the study, 69% of patients who underwent complete ablation had no visible disease at first endoscopic evaluation, compared with 40% of patients who underwent chemoablation therapy.
Source: Urology TimesCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A study led by fellow Dr. Craig Labbate shows promising results for using UGN-101 after a complete endoscopic ablation for patients with upper tract urothelial carcinoma. Learn about his research: https://t.co/BglOTeZrMC @urologytimes @AmerUrological @labbdoc #AUA23 #EndCancer
-
-
Mashup Score: 0Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC - 1 year(s) ago
Benjamin H. Lowentritt, MD, FACS, highlights key findings from the retrospective study of second-generation ARSI use in patients with metastatic castration-sensitive prostate cancer treated in clinic and discusses several directions for future analyses of real-world outcomes in prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC @UroDrBen @ChesUrology @AmerUrological #AUA23 #pcsm https://t.co/PUt1NHHD14
-
-
Mashup Score: 0
“We have become more advanced over time. We understand that men’s health is more than just testosterone. Men’s health is more than just erectile function and prostate disease,” says Michael D. Lutz, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Michael Lutz discusses the expanding role of men’s health clinics in urology. #AUA23 #urology #urologist Watch now: https://t.co/zXxBpoCDhj
-
-
Mashup Score: 5Study Sheds Light on Effect of Type of Treatment on Race-based Differences in Prostate Cancer–Specific Survival - 1 year(s) ago
Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Although Black men with prostate cancer had a higher cumulative incidence of prostate cancer–specific mortality than White men with the disease, when managed with the same treatment, they achieved similar survival outcomes. @Putnam_Cole #pcsm #AUA23 https://t.co/IyrUL7NQTu https://t.co/ETzRnUDcvm
-
-
Mashup Score: 0
In this podcast, Prof. Igor Tsaur (DE), chief editor of the UROONCO PCa editorial board talks with Dr. Marcio Moschovas (US) about his abstract presentation at AUA2023, “Simultaneous hernia repair following robotic-assisted radical prostatectomy is safe with low rates of mesh-related complications”.
Categories: Latest Headlines, UrologyTweet-
🎙️ During #AUA23 Prof. Tsaur (DE) & @marciomoschovas discussed the latest findings on the "safety of simultaneous hernia repair after robotic-assisted radical prostatectomy (RARP)". ✔️ Minimal mesh-related complications 🎧Listen to this new #EAUpodcast 👉https://t.co/0686oNONjV https://t.co/zlIlFeKGyw
-
-
Mashup Score: 0Enzalutamide Associated With Lower Metastases Risk Vs Leuprolide Alone in High-Risk nmHSPC - 1 year(s) ago
Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide. #prostatecancer #pcsm #AUA23 #oncology #nursing @AmerUrological https://t.co/9nVqHC0Mfa https://t.co/YniWa1hYkK
-
Dr. Siamak Daneshmand highlights positive TAR-200 data from the phase 2b SUNRISE-1 trial in BCG-unresponsive NMIBC. #AUA23 #urology #urologist @USC_Urology Watch now: https://t.co/i2uGiYCo1b